These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 36240247

  • 41. The impact of migration-related characteristics on the risk of TORCH infections among women of childbearing age: a population-based study in southern China.
    Li R, Han L, Xiong W, Wang W, Fan C, Li M, Liu X, Ling L.
    BMC Public Health; 2023 Feb 16; 23(1):351. PubMed ID: 36797787
    [Abstract] [Full Text] [Related]

  • 42. Association between TORCH infection and lupus anticoagulant antibody in pregnant women with recurrent abortion.
    Fatah HR.
    Cell Mol Biol (Noisy-le-grand); 2023 Dec 10; 69(13):162-166. PubMed ID: 38158672
    [Abstract] [Full Text] [Related]

  • 43. TORCH serologies and specific IgM antibody determination in acquired and congenital infections.
    Fung JC, Tilton RC.
    Ann Clin Lab Sci; 1985 Dec 10; 15(3):204-11. PubMed ID: 2986514
    [Abstract] [Full Text] [Related]

  • 44. TORCH Infections.
    Awadalla M, Liu A.
    Pediatr Ann; 2023 Nov 10; 52(11):e400-e406. PubMed ID: 37935398
    [Abstract] [Full Text] [Related]

  • 45. Prevalence of toxoplasmosis, cytomegalovirus and rubella IgG antibodies in Hatay women and children.
    Koksaldi-Motor V, Evirgen O, Azaroglu I, Inci M, Ozer B, Arica S.
    West Indian Med J; 2012 Mar 10; 61(2):154-7. PubMed ID: 23155962
    [Abstract] [Full Text] [Related]

  • 46. Epidemiology of Toxoplasma and CMV serology and of GBS colonization in pregnancy and neonatal outcome in a Sicilian population.
    Puccio G, Cajozzo C, Canduscio LA, Cino L, Romano A, Schimmenti MG, Giuffrè M, Corsello G.
    Ital J Pediatr; 2014 Feb 22; 40():23. PubMed ID: 24559197
    [Abstract] [Full Text] [Related]

  • 47. Is screening of TORCH worthwhile in women with bad obstetric history: an observation from eastern Nepal.
    Kumari N, Morris N, Dutta R.
    J Health Popul Nutr; 2011 Feb 22; 29(1):77-80. PubMed ID: 21528793
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Should we expand the TORCH complex? A description of clinical and diagnostic aspects of selected old and new agents.
    Kinney JS, Kumar ML.
    Clin Perinatol; 1988 Dec 22; 15(4):727-44. PubMed ID: 2850128
    [Abstract] [Full Text] [Related]

  • 50. [Prevalence of infectious agents in indigenous women of childbearing age in Venezuela].
    Monsalve-Castillo FM, Costa-León LA, Castellano ME, Suárez A, Atencio RJ.
    Biomedica; 2012 Dec 22; 32(4):519-26. PubMed ID: 23715227
    [Abstract] [Full Text] [Related]

  • 51. TORCH: a literature review and implications for practice.
    Haggerty L.
    J Obstet Gynecol Neonatal Nurs; 1985 Dec 22; 14(2):124-9. PubMed ID: 2987460
    [Abstract] [Full Text] [Related]

  • 52. Placentitis, with a new light on an old ToRCH.
    Altshuler G.
    Obstet Gynecol Annu; 1977 Dec 22; 6():197-221. PubMed ID: 200872
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Seroconversion and seroprevalence of TORCH infections in a pregnant women cohort study, Mombasa, Kenya, 2017-2019.
    Hunsperger E, Osoro E, Munyua P, Njenga MK, Mirieri H, Kikwai G, Odhiambo D, Dayan M, Omballa V, Agogo GO, Mugo C, Widdowson MA, Inwani I.
    Epidemiol Infect; 2024 Feb 02; 152():e68. PubMed ID: 38305089
    [Abstract] [Full Text] [Related]

  • 55. The Screening of Rubella Virus, Cytomegalovirus, Hepatitis B Virus, and Toxoplasma gondii Antibodies in Prepregnancy and Reproductive-Age Women in Tabriz, Iran.
    Nabizadeh E, Ghotaslou A, Salahi B, Ghotaslou R.
    Infect Dis Obstet Gynecol; 2022 Feb 02; 2022():4490728. PubMed ID: 35046632
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. ToRCH "co-infections" are associated with increased risk of abortion in pregnant women.
    Rasti S, Ghasemi FS, Abdoli A, Piroozmand A, Mousavi SG, Fakhrie-Kashan Z.
    Congenit Anom (Kyoto); 2016 Mar 02; 56(2):73-8. PubMed ID: 26499091
    [Abstract] [Full Text] [Related]

  • 58. Yield and costs of screening growth-retarded infants for torch infections.
    Khan NA, Kazzi SN.
    Am J Perinatol; 2000 Mar 02; 17(3):131-5. PubMed ID: 11012137
    [Abstract] [Full Text] [Related]

  • 59. TORCH screening in polyhydramnios: an observational study.
    Fayyaz H, Rafi J.
    J Matern Fetal Neonatal Med; 2012 Jul 02; 25(7):1069-72. PubMed ID: 21923307
    [Abstract] [Full Text] [Related]

  • 60. Seroprevalence of Toxoplasma, Rubella, CMV and HSV infection at a teaching hospital: A 7 year study from North India.
    Dinkar A, Singh J.
    J Family Med Prim Care; 2020 May 02; 9(5):2253-2257. PubMed ID: 32754483
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.